Business Context and Reporting Period
Company: AIKIDO PHARMA INC. (Note: Request metadata listed "Dominari Holdings Inc.", but the filing text identifies the registrant as AIKIDO PHARMA INC.)
Filing Type: Form 8-K (Current Report)
Date of Report: March 23, 2020
Reporting Period: Event date March 23, 2020; Record Date for dividend March 30, 2020.
The Company declared a dividend of one right per outstanding share of common stock to implement a poison pill plan designed to protect its net operating losses and other tax assets from limitations under Section 382 of the Internal Revenue Code.
Key Financial Metrics
This filing is a current report regarding a corporate governance action and does not contain audited financial statements, revenue, profit, cash flow, or debt metrics.
- Dividend: One Right per share of Common Stock.
- Exercise Price: $5.00 per Right (for 1/1,000th of a share of Series L Preferred Stock).
- Redemption Price: $0.0001 per Right (subject to adjustment).
- Preferred Stock Dividend: Greater of $1.00 per share or 1,000 times the Common Stock dividend.
- Voting Rights: Each share of Series L Preferred Stock entitles the holder to 1,000 votes.
Material Changes
The primary material change is the adoption of a Rights Agreement (poison pill) effective March 23, 2020.
- Trigger Threshold: Rights become exercisable if any person or group acquires beneficial ownership of 4.99% or more of the Common Stock (an "Acquiring Person").
- Expiration: Rights expire on October 23, 2023, unless earlier redeemed, exchanged, or terminated.
- Corporate Structure: The Board approved a Certificate of Designation for Series L Preferred Stock, filed with the Delaware Secretary of State on March 24, 2020.
Outlook, Risks, and Management Commentary
Purpose: The Rights Agreement is intended to discourage any person or group from acquiring 4.99% or more of the Company's stock, thereby preventing an "ownership change" that would limit the Company's ability to utilize tax benefits (net operating losses).
Key Provisions and Risks:
- Flip-In: If an Acquiring Person acquires 50% or more of the stock, other holders may exchange Rights for two shares of Common Stock per Right.
- Flip-Over: In a merger or asset sale after an Acquiring Person emerges, Rights may be exchanged for acquiring company stock with a market value equal to two times the Exercise Price.
- Redemption: The Board may redeem the Rights at $0.0001 per Right at any time before an Acquiring Person emerges.
- Qualifying Offer: Holders of 20% of outstanding shares may request a special meeting to vote on exempting a qualifying offer from the Rights Agreement if the Board does not act within 90 days.
Investor Verification Checklist
- Verify the exact number of outstanding shares of Common Stock as of the Record Date (March 30, 2020) to determine the total number of Rights issued.
- Confirm the current status of the Company's net operating losses (NOLs) and the specific tax benefits the Rights Agreement is designed to protect.
- Review the full text of the Rights Agreement (Exhibit 4.1) for specific exceptions to the 4.99% threshold and derivative treatment.
- Monitor for any future announcements regarding the redemption of Rights or the emergence of an Acquiring Person.
- Check subsequent filings for any amendments to the Series L Preferred Stock designation.